Current management of the myeloproliferative disorders: A case-based review

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 8, 2006, Pages 1151-1156

  Rice, Lawrence ^a   Baker, Kelty R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; ANTIHISTAMINIC AGENT; ANTITHROMBOCYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CLOPIDOGREL; CYTOTOXIC AGENT; DANAZOL; DIPYRIDAMOLE; ERYTHROPOIETIN; FOLIC ACID; HYDROXYUREA; IMATINIB; MERCAPTOPURINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PHENOTHIAZINE DERIVATIVE; PYRIDOXINE; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; ARTERY THROMBOSIS; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CYTAPHERESIS; CYTOREDUCTION; DIAGNOSTIC VALUE; DIARRHEA; DRY SKIN; EDEMA; ERYTHROMELALGIA; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; INDIVIDUALIZATION; LEG ULCER; LEUKEMIA; LEUKEMOGENESIS; LEUKOPENIA; LOW DRUG DOSE; MOLECULAR BIOLOGY; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NAUSEA; ORTHOSTATIC HYPOTENSION; PHLEBOTOMY; POLYCYTHEMIA VERA; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SICKLE CELL ANEMIA; SIDE EFFECT; SPLENECTOMY; SPLENOMEGALY; SURVIVAL; THROMBOCYTOPENIA; THROMBOCYTOPHERESIS; THROMBOSIS; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PHLEBOTOMY; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; THROMBOCYTHEMIA, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 33746675018     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia: a statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232.
2. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656-664.
3. Gardner FH. Early approaches in the treatment of polycythemia vera. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, Pa: WB Saunders; 1995:147-153.
4. Thomas DJ, Marshall J, Ross Russell RW, et al. Effect of hematocrit on cerebral blood flow in man. Lancet. 1977;2(8045):941-943.
5. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: a summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, Pa: WB Saunders; 1995:66-194.
6. Finazzi G, Barbui T. Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev. 2005;19:243-252.
7. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
8. Pardanani A, Tefferi A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood. 2004;104:1931-1939.
9. Buss DH, Cashell AW, O'Connor ML, Richards F II, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96:247-253.
10. Rice L, Popat U. Every case of essential thrombocythemia should be tested for the Philadelphia chromosome. Am J Hematol. 2005;78:71-73.
11. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001; 76:22-28.
12. Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol. 2003;16:227-242.
13. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995; 332:1132-1136.
14. Regev A, Stark P, Blickstein D, Lahav M. Thrombotic complications in essential thrombocythemia with relatively low platelet counts. Am J Hematol. 1997; 56:168-172.
15. Tefferi A, Silverstein MN, Petitt RM, et al. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost. 1997;23:379-383.
16. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33-45.
17. Elliott MA, Tefferi A. Interferon-alpha therapy in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost. 1997;23:463-472.
18. Baron BW, Mick R, Barron JM. Combined plateletpheresis and cytotoxic chemotherapy for symptomatic thrombocytosis in myeloproliferative disorders. Cancer. 1993;72:1209-1218.
19. Cervantes R, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol. 1998;102:684-690.
20. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with the new scoring system. Blood. 1996;88:1013-1018.
21. Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica. 2000;85:595-599.
22. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol. 2004;127:399-403.
23. Lofvenberg E, Wahlin A. Management of polycythaemia vera: essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol. 1988; 41:375-381.
24. Tefferi A, Mesa RA, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226-2233.
25. Mesa RA, Elliott MA, Schroeder G, Tefferi A. Durable responses to thalidomide-based therapy for myelofibrosis with myeloid metaplasia. Mayo Clin Proc. 2004;79:883-889.
26. Deeg HJ, Appelbaum FR. Stem-cell transplantation for myelofibrosis. N Engl J Med. 2001;344:775-776.
27. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood. 2005;105:4115-4119.